Pfizer and Astellas Pharma have shared positive top-line results from a late-stage study of their androgen receptor signalling inhibitor Xtandi (enzalutamide) in a subset of prostate cancer patients.

Jacob E. Berchuck, MD, highlights novel findings pointing to androgen receptor signaling and Wnt pathway activation as key correlates of poor response to therapy.

The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2025 of $0.22 per Class A ordinary share. The dividend will be paid on ...

PFE's oncology unit is in focus ahead of Q2 results, with key drugs facing both rising demand and market pressure.

CMS proposes the 2026 Physician Fee Schedule (PFS), addressing payment disparities in oncology, but the community oncology ...

Strengthens Board of Directors with appointment of two new independent members, increasing independent representation to greater than 90%Underscores Royalty Pharma’s commitment to enhanced corporate ...

Essa Pharma, which had been resisting pressure from activist investors to wind down operations, has now agreed a deal to ...

Carotuximab plus Erleada proved safe in the first 10 patients with metastatic castration-resistant prostate cancer dosed on ...

Corcept Therapeutics CORT announced that it has submitted a new drug application (NDA) to the FDA seeking approval for its ...

Pfizer says new oncology division will generate eight new blockbusters by 2030, in first R&D update after its $43bn takeover of Seagen.

Astellas has become the first drugmaker to bring a drug in the neurokinin 3 (NK3) receptor antagonist class to the US market, after getting FDA approval of fezolinetant for a common and ...

Over the coming years, the Inflation Reduction Act aims to help those with Medicare save on their prescription drug costs. Learn more.